Meta-analysisindependent cross-checkabstract checked★ key study I-ODD-112 in-depth review
GLP-1 injections in 60,080 people: fewer deaths, no more pancreas problems
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Overview
Sattar N et al.. Lancet Diabetes Endocrinol 2021 · PMID 34425083 · DOI 10.1016/S2213-8587(21)00203-5
Death HR 0.88; MACE HR 0.86; no increase in pancreatic adverse effects.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Pool GLP-1 RA outcome trials.
- How was the study done?
Meta-analysis of 8 RCTs.
- How many people, animals or samples were studied?
60,080 patients.
- What was actually found?
Benefits on heart, kidney and survival; no pancreatic safety signal.
- How large was the observed effect?
MACE -14%, death -12%.
- What do the results mean in everyday life?
In large trials these drugs prolonged life and did not cause more pancreatitis.
- What are the study's limitations?
Exact pancreatitis numbers not in abstract.
- What does it say about Elawady's specific claim?
Contradicts a clear pancreatitis risk and net harm.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Very rare effects.
Scientific in-depth review
1. Full reference
- Authors
- Sattar N et al.
- Journal
- Lancet Diabetes Endocrinol
- Year
- 2021
- Identifier
- PMID 34425083 DOI 10.1016/S2213-8587(21)00203-5
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Funding: none (abstract). Author disclosures not reviewed.
2. Research question
What are the cardiovascular, mortality, kidney and safety effects of GLP-1 RAs in type 2 diabetes?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and meta-analysis of large placebo-controlled cardiovascular outcome trials
- Population
Patients with type 2 diabetes in cardiovascular outcome trials (>500 patients)
- Country
International
- Period
Searches to 9 June 2021
- Sample size
8 trials, 60,080 patients
- Inclusion and exclusion criteria
Placebo-controlled GLP-1 RA trials with MACE primary outcome
4. Methods and endpoints
- Exposure / intervention
GLP-1 RAs (injectable or oral)
- Comparator
Placebo
- Endpoints
MACE, components, all-cause death, HF hospitalisation, kidney composite; safety: severe hypoglycaemia, retinopathy, pancreatitis, pancreatic cancer
- Statistical methods
Random-effects HR; odds ratios for safety outcomes
5. Actual results
- Results
MACE HR 0.86 (0.80-0.93); all-cause death HR 0.88 (0.82-0.94); HF hospitalisation HR 0.89 (0.82-0.98); kidney composite HR 0.79 (0.73-0.87); no increase in severe hypoglycaemia, retinopathy or pancreatic adverse effects.
- Absolute risks
Not reported in abstract.
- Authors' conclusion
GLP-1 RAs reduce MACE components, all-cause mortality, HF hospitalisation and worsening kidney function.
6. Strengths
- Large blinded outcome trials with adjudicated pancreatitis
- Long follow-up compared with glycaemic trials
7. Weaknesses
- Only 8 trials
- Pancreatitis results reported qualitatively in abstract
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
PROSPERO-registered; constituent trials at low risk of bias.
9. Assessment of the statistical interpretation
Pancreatitis effect stated as 'no increase'; exact OR not in abstract.
10. Relevance to the specific claim
Large blinded trials found no excess pancreatitis (C-ODD-04) and a mortality benefit (C-ODD-06).
11. Independent contrary findings
Wen 2025 (I-ODD-113) pooled 62 mostly smaller RCTs and found RR 1.44.
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
High-quality evidence against a large pancreatitis risk; strong evidence of benefit.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | moderate |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Very small absolute pancreatitis increase cannot be excluded.
15. Linked fact checks
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies contradicting or limiting the claim
- Glucose-lowering drugs are net harmful and belong among the 'forbidden' items; dapagliflozin (Forxiga) is among the 'dirtiest' drugs and kills the brain; leg amputations happen only to people taking diabetes drugs and insulin. – Studies contradicting or limiting the claim